Nippon Shinyaku. 

Nippon Shinyaku Co., Ltd., founded in 1911 and based in Kyoto, Japan, is an established enterprise with international operations, including in Switzerland, focusing on the development, production, and sale of both pharmaceutical products and functional foods. The company's business activities are structured into its Pharmaceuticals and Functional Food segments. The Pharmaceuticals division is dedicated to researching, manufacturing, and marketing a wide spectrum of therapeutic agents. These medications target various medical conditions, including urological diseases (such as benign prostatic hyperplasia with Zalutia and Eviprostat, pollakisuria with Bladderon, and prostate cancer with Estracyt), erectile dysfunction (Cialis), inflammatory and allergic disorders (like Erizas and Livostin), and hematologic malignancies (including myelodysplastic syndrome with Vidaza, acute leukemia and malignant lymphoma with Cylocide and CylocideN, acute promyelocytic leukemia with Trisenox and Amnolake, and the anti-CD20 monoclonal antibody Gazyva). The portfolio also extends to treatments for cardiovascular and metabolic conditions (e.g., Uptravi, Adcirca, Opsumit for pulmonary arterial hypertension), gastrointestinal issues, and specialized disorders such as sinusoidal obstruction syndrome (Defiterio) and muscular dystrophy (VILTEPSO). Further offerings include medications for dysmenorrhea (Lunabel LD and Lunabel ULD), vertigo (Cephadol), Meniere's disease (Isobide), and pain management (Onetram and Tramal for cancer and chronic pain), alongside Azunol Gargle liquid and Regtect for alcohol abstinence. Beyond its current product line, the company actively invests in research and development for new drugs in the fields of gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment provides an assortment of products, such as ingredients for health foods, various preservatives, protein preparations, dietary supplements, and a selection of spices and condiments.